李慧锴, 李强. 肝癌多药耐药机制研究进展[J]. 中国肿瘤临床, 2013, 40(16): 1008-1010. DOI: 10.3969/j.issn.1000-8179.20131377
引用本文: 李慧锴, 李强. 肝癌多药耐药机制研究进展[J]. 中国肿瘤临床, 2013, 40(16): 1008-1010. DOI: 10.3969/j.issn.1000-8179.20131377
Huikai Li, Qiang Li. Mechanisms of Multidrug-resistance in hepatocellular carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(16): 1008-1010. DOI: 10.3969/j.issn.1000-8179.20131377
Citation: Huikai Li, Qiang Li. Mechanisms of Multidrug-resistance in hepatocellular carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(16): 1008-1010. DOI: 10.3969/j.issn.1000-8179.20131377

肝癌多药耐药机制研究进展

Mechanisms of Multidrug-resistance in hepatocellular carcinoma

  • 摘要: 原发性肝癌是我国常见的恶性肿瘤之一,化疗是中晚期肝癌综合治疗的重要手段,但肝癌化疗多药耐药现象严重阻碍了化疗的效果。目前肝癌多药耐药的机制仍不明确,主要包括跨膜转运蛋白泵药作用,细胞内酶系统改变,MAPK信号转导系统的激活,控制凋亡的基因和蛋白的改变,肿瘤微环境的影响等。近年随着研究的不断深入,又有新的相关机制报道,如内质网应激和microRNA在肝癌耐药中发挥着不可忽视的作用。本文就近年来肝癌多药耐药的相关研究进展做简要综述,为临床提供新的思路。

     

    Abstract: Hepatocellular carcinoma (HCC) is one of the common malignant tumors in China. The most important treatment for middle-late stage HCC is chemotherapy. However, the development of multidrug resistance (MDR) in HCC can dramatically reduce the efficacy of chemotherapeutic treatment. At present, the mechanisms regulating the development of MDR in HCC are still unknown. These mechanisms involve ATP-dependent drug efflux pump, enzymatic deactivation, the activation of MAPK signal pathway, apoptosis gene and protein changing, the influence of the tumor microenvironment, and so on. With the development of the research, some new mechanisms are found, such as the endoplasmic reticulum stress and the effect of microRNA, which cannot be ignored. This review aims to summarize the mechanisms of MDR in HCC and discuss potential therapeutic targets for anticancer intervention.

     

/

返回文章
返回